{"id":43025,"date":"2016-03-10T00:00:00","date_gmt":"2016-03-09T23:00:00","guid":{"rendered":"https:\/\/techma.bakertilly.es\/caixa-capital-risk-invierte-en-inbiomotion\/"},"modified":"2025-03-12T11:38:47","modified_gmt":"2025-03-12T10:38:47","slug":"caixa-capital-risk-invierte-en-inbiomotion","status":"publish","type":"post","link":"https:\/\/techma.bakertilly.es\/en\/caixa-capital-risk-invierte-en-inbiomotion\/","title":{"rendered":"Caixa Capital Risk invests in Inbiomotion"},"content":{"rendered":"
It seems that biotechnology is finding investors in our country. A few weeks ago we told you that Inveready had invested in Cuantum and Ab-biotics, this week we learned that Oncostellae, which received a \u20ac1M round is looking for funding, and Caixa Capital Risk has led a \u20ac2.2M round in Inbiomotion.<\/span><\/h6>\n

la Caixa's investment in Inbiomotion<\/strong><\/span><\/p>\n

La Caixa, through Caixa Innvierte BioMed II, has led a \u20ac2.2M round of funding in Inbiomotion<\/a>,<\/span> a spin-off of the Barcelona Biomedical Research Institute that develops diagnostic tests to predict the risk of cancer patients suffering from bone metastasis.<\/span><\/p>\n

Also participating in the round were Ysios Capital<\/a><\/span>the leading Spanish investment manager in the biotechnology sector, through its Ysios BioFund I, and the Vila Casas Foundation, which were already shareholders of the company.<\/span><\/p>\n

This round will complete the clinical validation and make Inbiomotion's first product available to patients.<\/span><\/p>\n

Inbiomotion's product, Osteomet, has already been validated in more than 1,300 patient samples from independent, multi-country cohorts and the company's primary goal is to complete its clinical and regulatory development within the next 2 years.<\/span><\/p>\n

La Caixa is committed to biotechnology and creates Caixa Innvierte Start.<\/strong><\/span><\/p>\n

It is also in the news that last December the Caixa<\/a><\/span> registered a new fund for technology SMEs with the CNMV, mainly for companies in the health and biotechnology sectors, although other sectors are not ruled out.<\/span><\/p>\n

\u00a0La Caixa will focus on Spanish start-ups (although it does not rule out the \"exceptional\" possibility of making purchases in other geographies as long as they do not consume 20% of the total resources raised by the fund) and with an outstanding potential for innovation and growth.<\/span><\/p>\n

These general guidelines are quite favourable for the new fund to receive the injection of the government's fund of funds articulated through the ICO, Fond-ICO Global<\/a><\/span> -whose sixth call remains open until 29 March. In fact, in the management regulations that Caixa Innvierte Start has submitted to the CNMV, there is a specific article (article 17) that regulates the intervention of public participants.<\/span><\/p>\n

If you are looking for financing, please contact us. Abra-Invest has a team of experts in alternative financing at your disposal. Call + 34 946424142 or fill in the contact form.<\/span><\/p>\n

Other posts that may interest you<\/span><\/strong><\/p>\n

Inveready bets on biotechnology, invests in Cuantum and AB-Biotics in less than a month<\/a><\/span><\/p>\n

Investors lose their fear of investing in biotechnology<\/a><\/span><\/p>\n

Biotech operations: Minoryx, Suanfarma, Ability Pharma and Oryzon Genomics<\/a><\/span><\/p>","protected":false},"excerpt":{"rendered":"

It seems that biotechnology is finding investors in our country. A few weeks ago we told you that Inveready had invested in Cuantum and Ab-biotics, this week we learned that Oncostellae, which received a \u20ac1M round is looking for funding, and Caixa Capital Risk has led a \u20ac2.2M round in Inbiomotion.<\/p>","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1750],"tags":[238,533],"sectores":[],"tipo-contenido":[2260],"class_list":["post-43025","post","type-post","status-publish","format-standard","hentry","category-financiacion-sectorial","tag-biotecnologia","tag-caixa","tipo-contenido-noticias"],"acf":[],"_links":{"self":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/43025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/comments?post=43025"}],"version-history":[{"count":0,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/43025\/revisions"}],"wp:attachment":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/media?parent=43025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/categories?post=43025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tags?post=43025"},{"taxonomy":"sectores","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/sectores?post=43025"},{"taxonomy":"tipo-contenido","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tipo-contenido?post=43025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}